Pharmaxis today announced that an advisory committee of the U.S. Food and Drug Administration (FDA) has voted to recommend the approval of Aridol™ (mannitol bronchial challenge test) for use as a bronchial test to assess bronchial hyperresponsiveness to aid in diagnosing patients who have symptoms of asthma or symptoms that are suggestive of asthma.

Read media release